Discussion group 1 TB preventive therapy for PLWHA Alasdair Reid for Fabio Scano THD unit Stop TB department WHO.

Slides:



Advertisements
Similar presentations
Adherence to Hepatitis C Therapies and The Impact of Comorbid Conditions Mary Cassler RPh, MBA, Lon Castle, M.D., Bill Dreitlein, Pharm.D., Mona Khalid,
Advertisements

TB/HIV Research Priorities: TB Preventive Therapy.
Tuberculosis (TB): clinical diagnosis and management of tuberculosis and measures for its prevention and control March 2006.
IPT and ICF Guidelines Update Reuben Granich HIV/AIDS Department World Health Organization Haileyesus Getahun STOP TB Department World Health Organization.
Delphine Sculier, MD,MPH Stop TB Department World Health Organisation Geneva, Switzerland Update on the revision of ART guidelines for TB patients.
Tuberculosis in Children: Prevention Module 10C - March 2010.
ARIAtlas.org. Global Impact TB causes nearly two million deaths a year, making it the world’s seventh most common cause of mortality. More than two billion.
CDC Recommendations for HIV Testing of Adults and Adolescents Christina Price, MPH Delta Region AIDS Education and Training Center.
Principles of care of the HIV-1 infected pregnant mother Protection of mothers from mono- and dual- therapies likely to induce resistance: Women refusing.
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.
1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
TBLI and HIV.  30% of People infected with HIV/AIDS and have latent TB will eventually get active TB (5 -10% /year).In HIV negative 5-10 % during their.
Prevention Bacille Calmette Guerin (BCG) Vaccine Live attenuated strain of Mycobacterium bovis; 1921 Efficacy Clinical trials UK: protective effect of.
S AFETY OF I SONIAZID P REVENTIVE T HERAPY A MONG HIV- INFECTED P REGNANT W OMEN IN H IGH TB I NCIDENCE S ETTINGS : STUDY UPDATE OF IMPAACT P1078 (APPRISE)
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Unit 5: IPT Isoniazid TB Preventive Therapy
Current international guidelines recommend 6–9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in.
Impact evaluation Evaluate new tools Translate new knowledge into policy and implementation Knowledge gap Program implementation.
Module 14: Isoniazid Preventive Therapy Programme.
Tuberculosis in Pregnancy Max Brinsmead MB BS PhD May 2015.
Three key messages on tuberculosis control World Tuberculosis Day 2010 ECDC TB Team European Centre for Disease Prevention and Control Stockholm, 24 March.
Johns Hopkins Center for Tuberculosis Research
Isoniazid preventive therapy in a time of HIV, TB, and MDR.
Concept Sheet Development: Developing the Question Kara Wools-Kaloustian M.D. M.S.
Progress of the Singapore TB Elimination Programme (STEP)
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Haileyesus Getahun Stop TB Department WHO Re-conceptualizing ICF and IPT: global progress to date 14 th Core Group Meeting of the TB/HIV Working Group,
Revising the research priorities for HIV/TB Haileyesus Getahun Delphine Sculier Stop TB Department.
Effect of community-wide isoniazid preventive therapy on tuberculosis among South African gold miners “Thibelo TB” Aurum Health Research LSHTM JHU Gold.
Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.
The Epidemiology of Tuberculosis Lex Gibson, Virginia TB Program.
California Update : TB Epidemiology and Indicators CTCA October 22, 2010 Jennifer Flood MD MPH Chief, Surveillance and Epidemiology Tuberculosis Control.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
PreP Adherence Clubs. MSF ART Adherence clubs ART Adherence clubs are long term retention model of care catering for stable ART patients Based on a quick.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.
The Epidemiology of Tuberculosis Lex Gibson, Director Virginia TB Program.
HIV and Pregnancy. Introduction In the general obstetrical population in the United States, the frequency of HIV infection is about 1 per The prevalence.
Roundtable. Detection and treatment of TB Andrew Black.
PRE-EXPOSURE PROPHYLAXIS in Pregnancy in South Africa
Management of the Newborn When Maternal TB Suspected
IMPAACT 2001 STUDY Mhembere T.P. (B. Pharm (Hons), MPH)
هدف كلي برنامه كنترل سل:
Guidance on completion of Isoniazid Preventive Therapy register
Infant born with mother Tuberculosis
Treatment of TB Disease
2017 Key Considerations for adolescents and children & Key populations
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
Treatment of Latent TB Infection (LTBI)
R Nagar 1, Debashish Kundu2, S Chandra2 , A Khanna1
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
پروتكل آموزش سلامت به مددجو
Discussion group 1 Barriers to implementation of IPT
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
Tuberculosis Global Epidemiology
Chen S, Dong Y, Kiuchi MG, et al
TB/HIV COLLABORATION IN UGANDA
Cotrimoxazole Prophylaxis in HIV positive individuals Group A
Anthony D Harries Ministry of Health, Malawi
Latent TB Infection among Diabetic patients
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Care for those with HIV/TB: HBC, palliative care, CPT, IPT, STI, nutritional and psychological support. All the interventions should be considered within.
Latent TB Infection (LTBI)
5th edition NTP MANUAL OF PROCEDURES Case Finding
DSD and TB/HIV services in Zimbabwe
Preventing recurrent TB in high HIV-prevalent areas
Procedures (Decision on Diagnosis based on Laboratory Results)
Presentation transcript:

Discussion group 1 TB preventive therapy for PLWHA Alasdair Reid for Fabio Scano THD unit Stop TB department WHO

What do we know? What do we need to know? What has to be done to fill the knowledge gap? What to do in the meantime?

What do we know? Preventing first episode of TB 3 systematic reviews/meta-analyses IPT causes significant reduction of TB incidence (50-60% reduction) in HIV+/PPD+ individuals 40% reduction in HIV+ PPD unknown individuals Duration of effect - limited evidence but likely to decline with time

What do we know? Preventing first episode of TB (2) Short course Rifampicin containing regimens as effective as IPT but higher SE No demonstrable effect on mortality Adherence – very variable and may depend on length of treatment and selection criteria Cost-effectiveness – limited data but suggest cost-effective Feasibility - uncertain

What do we know? Preventing first episode of TB (3) Simple symptom screening questionnaire as effective as CXR in excluding active TB Use in pregnancy uncertain Use of IPT in settings with high background INH resistance - unclear No evidence that drug resistance increased by PT Breastfeeding infants of sm+ mothers and household contacts <5 plus BCG

What do we know? Preventive treatment aimed at preventing recurrent TB Evidence of effect of IPT in preventing recurrent TB in PLWHA

Ongoing research CDC: 3/12 INH+RFP vs 9/12 INH 6/12 IPT vs lifelong IPT CREATE: Lifelong IPT in SA mineworkers IPT and ART in Rio Impact of ICF and community interventions including IPT in Zambia & SA

Ongoing research South Africa 4 arm study 6/12 INH v lifelong INH v 3/12 RFP/INH v 3/12 RMP/INH Botswana National IPT programme since 2003 Evaluation in 2005 linked to DRS (1995/6, 1999, 2002) USAID - India 6/12 EH vs 3yrs INH NIAID INH to infants of HIV positive mothers

What do we need to know? The research questions similar for primary or secondary PT Establish optimal regimens (drugs & duration) & operational feasibility of PT in high HIV prevalence settings Role of PT in developing drug resistance and impact of drug resistance on efficacy of PT What is public health benefit (cost-effectiveness and impact) of large scale PT in high HIV prevalence settings. Incident TB may be higher in HIV-infected patients with a low CD4 count. Should this be a targeted group? Efficacy & safety of routine IPT for HIV+ pregnant women Feasibility of PT programmes in the context of ART scale-up national plans

What has to be done to fill the knowledge gap? RCT of ART +/- PT needed to answer the question about added efficacy CREATE project in Brazil Best way of delivering PT in routine setting Development of a valid screening tool Studies looking at the effect of PT programmes on the emergence of anti-TB drug resistance (to any drug) A pilot phase study is needed in order to determine the efficacy and safety of PT for pregnant women

What to do in the meantime? IPT should be offered as part of a minimum package of care for PLWH on grounds of its efficacy at individual level. Ongoing studies will show if mass PT will be an adjunctive tool to control TB in high HIV prevalence settings (CREATE). Emergence of drug resistance due to use of PT & implementation of PT programmes in settings with high drug resistance to any drug needs careful evaluation, eg Botswana. Not enough evidence to suggest that PT contributes to drug resistance but high compliance should be encouraged. CXR not necessary to exclude active TB in asymptomatic subjects, symptom screening questionnaire imperative. International guidelines need updating and programmes should develop simple tools and train HCW in use of screening tools. Given limited data, PT cannot be recommended for eligible pregnant women on a routine basis.